This report was recently updated on April 12 2024 with the latest and most recent
market numbers
Global Pharmacogenomics Market Size, Trends & Analysis - Forecasts to 2028 By Technology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, and Mass Spectrometry), By Application (Drug Discovery, Pain Management, Neurology, Oncology, Cardiovascular Diseases, Infectious Diseases, Psychiatry, and Others), By End User (Hospitals, Clinics, Research Institute, and Medical, Academic Institute), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global pharmacogenomics market is projected to grow at a CAGR of 9.6% from 2023 to 2028.
Pharmacogenomics market growth is driven by the advancement in genomics, including the completion of the human genome project, which has provided a wealth of genetic information that can be utilized for pharmacogenomic research. This has enabled the identification of genetic variations associated with drug responses and side effects. Pharmacogenomics plays a vital role, where medication or treatment is customized for an individual's genetic profile. This approach has gained popularity because it has the potential to enhance the effectiveness of drugs while minimizing adverse reactions.
Furthermore, the market growth is also driven by various pharmacogenomics applications, including personalized drug selection and dosing, optimizing pharmacogenomics in cancer treatment, tailoring cardiovascular and psychiatric medications, managing pain, preventing adverse drug reactions, and guiding clinical trials and drug labelling.
Pharmaceutical companies are increasingly adopting pharmacogenomic data into their drug development channels. This enables them to develop more effective drugs and have a higher likelihood of success in clinical trials. The development of targeted therapies designed specifically for patients with specific genetic markers has created a strong demand for pharmacogenomic testing services to identify suitable candidates for these treatments.
However, a shortage of skilled workers in pharmacogenomics can impede the market's growth despite advancements that enhance drug effectiveness and reduce adverse reactions. New techniques and approaches necessitate specialized skills, and the scarcity of qualified personnel may hinder market expansion. Proficient healthcare professionals are crucial for safe and effective patient treatments in pharmacogenomics.
The polymerase chain reaction (PCR) segment is expected to hold the largest share of the market over the forecast period. This dominance can be attributed to the advantages of PCR, such as its ability to analyze small samples for detecting microbial agents in a relatively short time, typically taking 4-8 hours, which is approximately three times faster than alternative methods. Furthermore, introducing new technology related to PCR drives the segment's growth. For instance, in September 2021, QuantStudio Absolute Q Digital PCR System, a comprehensive digital PCR (dPCR) technology, was introduced by Thermo Fisher Scientific Inc., which is aimed at promptly delivering exceptionally accurate results.
The DNA sequencing segment is expected to be the fastest-growing segment in the market from 2023-2028. This growth is attributed to advancements in DNA sequencing technologies, enabling comprehensive genetic analysis. Such progress enhances the capacity to provide personalized medicine, develop drugs, and comprehend the genetic variation in drug response.
The drug discovery segment is anticipated to be the fastest-growing segment in the market from 2023-2028. Pharmacogenomics enhances drug effectiveness and reduces adverse effects. For instance, according to Drug Metabolism Reviews in April 2021, research shows that pharmacogenomics supports in identifying drug responders, non-responders, and those at risk of adverse reactions, thereby accelerating medication development and preventing failures. Genomic data is incorporated into various drug development stages for this purpose.
The oncology segment is expected to hold the largest share of the market over the forecast period. Pharmacogenomics plays a significant role in optimizing drug therapy and developing more efficient treatments tailored to individual genomes. Oncology stands out as the leading application due to the rising global cancer prevalence, increased demand from healthcare providers, and the development of more efficient, lower side-effect drug therapies to combat the disease effectively.
The medical, academic institute segment is anticipated to be the fastest-growing segment in the market from 2023-2028. The anticipated growth is due to increasing recognition of the importance of pharmacogenomics in personalized medicine. As healthcare providers and researchers better understand patient response to drugs, academic institutions have become hubs for in-depth research and education in this field. This growing awareness motivates students and professionals to engage in pharmacogenomics research and practice, further fuelling the segment's growth.
The hospital segment is projected to hold the largest share of the market over the forecast period. The growth is attributed to the growing demand and heightened awareness among healthcare professionals about the advanced laboratories and specialized pharmacogenomics units, which provide superior technology, such as advanced drug development technologies, to a highly trained workforce.
North America is expected to be the largest region in the market. The primary reasons boosting the regional market growth include the increasing prevalence of chronic diseases like cancer and cardiovascular conditions, driving demand for personalized medicine and pharmacogenomics-based therapies. The rising aging population and increasing investments in healthcare infrastructure and R&D also contribute to this region's prominence.
Asia Pacific is predicted to witness rapid growth during the forecast period. This growth is attributed to a diverse population, a rising prevalence of chronic illnesses, technological advancements, and an increasing demand for precision medicine. This region's growing incidence of chronic diseases contributes to the increasing demand for personalized medicine and precise therapies. Countries such as China, Japan, and India are witnessing increased genetic testing facilities, research partnerships, and government efforts to promote precision medicine and pharmacogenomics.
Abbott, Bayer AG, Novartis AG, AbbVie Inc, Teva Pharmaceutical Industries ltd, Natco Pharma Limited, Lupin, Sun Pharmaceutical Industries ltd, Merck & Co Inc, and Eli Lilly and Company, among others, are some of the key players operating in the global pharmacogenomics market.
Please note: This is not an exhaustive list of companies profiled in the report.
In May 2022, Invitae, a personalized medicine genetics company, introduced a Pharmacogenomics (PGx) Panel encompassing a dedicated Mental Health Panel and a clinical decision support tool (CDST). This comprehensive offering analyzes patients' genetics and concurrent medications to personalize drug selection and dosages.
In January 2023, QIAGEN, a global biotechnology company, entered an exclusive partnership with Helix, a population genomics leader based in California, to advance companion diagnostics for hereditary diseases.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL PHARMACOGENOMICS MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL PHARMACOGENOMICS MARKET, BY APPLICATION
4.1 Introduction
4.2 Pharmacogenomics Market: Application Scope Key Takeaways
4.3 Revenue Growth Analysis, 2022 & 2028
4.4 Drug Discovery
4.4.1 Drug Discovery Market Estimates and Forecast, 2020-2028 (USD Million)
4.5 Pain Management
4.5.1 Pain Management Market Estimates and Forecast, 2020-2028 (USD Million)
4.6 Neurology
4.6.1 Neurology Market Estimates and Forecast, 2020-2028 (USD Million)
4.7 Oncology
4.7.1 Oncology Market Estimates and Forecast, 2020-2028 (USD Million)
4.8 Cardiovascular Diseases
4.8.1 Cardiovascular Diseases Market Estimates and Forecast, 2020-2028 (USD Million)
4.9 Infectious Diseases
4.9.1 Infectious Diseases Market Estimates and Forecast, 2020-2028 (USD Million)
4.10 Psychiatry
4.10.1 Psychiatry Market Estimates and Forecast, 2020-2028 (USD Million)
4.11 Others
4.11.1 Others Market Estimates and Forecast, 2020-2028 (USD Million)
5 GLOBAL PHARMACOGENOMICS MARKET, END USER
5.1 Introduction
5.2 Pharmacogenomics Market: End User Scope Key Takeaways
5.3 Revenue Growth Analysis, 2022 & 2028
5.4 Hospitals
5.4.1 Hospitals Market Estimates and Forecast, 2020-2028 (USD Million)
5.5 Clinics
5.5.1 Clinics Market Estimates and Forecast, 2020-2028 (USD Million)
5.6 Research Institute
5.6.1 Research Institute Market Estimates and Forecast, 2020-2028 (USD Million)
5.7 Medical, Academic Institute
5.7.1 Medical, Academic Institute Market Estimates and Forecast, 2020-2028 (USD Million)
6 GLOBAL PHARMACOGENOMICS MARKET, BY TECHNOLOGY
6.1 Introduction
6.2 Pharmacogenomics Market: Technology Scope Key Takeaways
6.3 Revenue Growth Analysis, 2022 & 2028
6.4 DNA Sequencing
6.4.1 DNA Sequencing Market Estimates and Forecast, 2020-2028 (USD Million)
6.5 Microarray
6.5.1 Microarray Market Estimates and Forecast, 2020-2028 (USD Million)
6.6 Polymerase Chain Reaction
6.6.1 Polymerase Chain Reaction Market Estimates and Forecast, 2020-2028 (USD Million)
6.7 Electrophoresis
6.7.1 Electrophoresis Market Estimates and Forecast, 2020-2028 (USD Million)
6.8 Mass Spectrometry
6.8.1 Mass Spectrometry Market Estimates and Forecast, 2020-2028 (USD Million)
7 GLOBAL PHARMACOGENOMICS MARKET, BY REGION
7.1 Introduction
7.2 North America Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.2.1 By Application
7.2.2 End User
7.2.3 By Technology
7.2.4 By Country
7.2.4.1 U.S. Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.2.4.1.1 By Application
7.2.4.1.2 End User
7.2.4.1.3 By Technology
7.2.4.2 Canada Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.2.4.2.1 By Application
7.2.4.2.2 End User
7.2.4.2.3 By Technology
7.2.4.3 Mexico Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.2.4.3.1 By Application
7.2.4.3.2 End User
7.2.4.3.3 By Technology
7.3 Europe Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.3.1 By Application
7.3.2 End User
7.3.3 By Technology
7.3.4 By Country
7.3.4.1 Germany Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.1.1 By Application
7.3.4.1.2 End User
7.3.4.1.3 By Technology
7.3.4.2 U.K. Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.2.1 By Application
7.3.4.2.2 End User
7.3.4.2.3 By Technology
7.3.4.3 France Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.3.1 By Application
7.3.4.3.2 End User
7.3.4.3.3 By Technology
7.3.4.4 Italy Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.4.1 By Application
7.3.4.4.2 End User
7.2.4.4.3 By Technology
7.3.4.5 Spain Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.5.1 By Application
7.3.4.5.2 End User
7.2.4.5.3 By Technology
7.3.4.6 Netherlands Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.6.1 By Application
7.3.4.6.2 End User
7.2.4.6.3 By Technology
7.3.4.7 Rest of Europe Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.3.4.7.1 By Application
7.3.4.7.2 End User
7.2.4.7.3 By Technology
7.4 Asia Pacific Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.1 By Application
7.4.2 End User
7.4.3 By Technology
7.4.4 By Country
7.4.4.1 China Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.1.1 By Application
7.4.4.1.2 End User
7.4.4.1.3 By Technology
7.4.4.2 Japan Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.2.1 By Application
7.4.4.2.2 End User
7.4.4.2.3 By Technology
7.4.4.3 India Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.3.1 By Application
7.4.4.3.2 End User
7.4.4.3.3 By Technology
7.4.4.4 South Korea Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.4.1 By Application
7.4.4.4.2 End User
7.4.4.4.3 By Technology
7.4.4.5 Singapore Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.5.1 By Application
7.4.4.5.2 End User
7.4.4.5.3 By Technology
7.4.4.6 Malaysia Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.6.1 By Application
7.4.4.6.2 End User
7.4.4.6.3 By Technology
7.4.4.7 Thailand Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.7.1 By Application
7.4.4.7.2 End User
7.4.4.7.3 By Technology
7.4.4.8 Indonesia Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.8.1 By Application
7.4.4.8.2 End User
7.4.4.8.3 By Technology
7.4.4.9 Vietnam Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.9.1 By Application
7.4.4.9.2 End User
7.4.4.9.3 By Technology
7.4.4.10 Taiwan Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.10.1 By Application
7.4.4.10.2 End User
7.4.4.10.3 By Technology
7.4.4.11 Rest of Asia Pacific Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.4.4.11.1 By Application
7.4.4.11.2 End User
7.4.4.11.3 By Technology
7.5 Middle East and Africa Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.5.1 By Application
7.5.2 End User
7.5.3 By Technology
7.5.4 By Country
7.5.4.1 Saudi Arabia Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.5.4.1.1 By Application
7.5.4.1.2 End User
7.5.4.1.3 By Technology
7.5.4.2 U.A.E. Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.5.4.2.1 By Application
7.5.4.2.2 End User
7.5.4.2.3 By Technology
7.5.4.3 Israel Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.5.4.3.1 By Application
7.5.4.3.2 End User
7.5.4.3.3 By Technology
7.5.4.4 South Africa Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.5.4.4.1 By Application
7.5.4.4.2 End User
7.5.4.4.3 By Technology
7.5.4.5 Rest of Middle East and Africa Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.5.4.5.1 By Application
7.5.4.5.2 End User
7.5.4.5.2 By Technology
7.6 Central and South America Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.6.1 By Application
7.6.2 End User
7.6.3 By Technology
7.6.4 By Country
7.6.4.1 Brazil Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.6.4.1.1 By Application
7.6.4.1.2 End User
7.6.4.1.3 By Technology
7.6.4.2 Argentina Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.6.4.2.1 By Application
7.6.4.2.2 End User
7.6.4.2.3 By Technology
7.6.4.3 Chile Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.6.4.3.1 By Application
7.6.4.3.2 End User
7.6.4.3.3 By Technology
7.6.4.4 Rest of Central and South America Pharmacogenomics Market Estimates and Forecast, 2020-2028 (USD Million)
7.6.4.4.1 By Application
7.6.4.4.2 End User
7.6.4.4.3 By Technology
8 COMPETITIVE LANDCAPE
8.1 Company Market Share Analysis
8.2 Four Quadrant Positioning Matrix
8.2.1 Market Leaders
8.2.2 Market Visionaries
8.2.3 Market Challengers
8.2.4 Niche Market Players
8.3 Vendor Landscape
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 Rest of the World
8.4 Company Profiles
8.4.1 Abbott
8.4.1.1 Business Description & Financial Analysis
8.4.1.2 SWOT Analysis
8.4.1.3 Products & Services Offered
8.4.1.4 Strategic Alliances between Business Partners
8.4.2 Bayer AG
8.4.2.1 Business Description & Financial Analysis
8.4.2.2 SWOT Analysis
8.4.2.3 Products & Services Offered
8.4.2.4 Strategic Alliances between Business Partners
8.4.3 AbbVie Inc
8.4.3.1 Business Description & Financial Analysis
8.4.3.2 SWOT Analysis
8.4.3.3 Products & Services Offered
8.4.3.4 Strategic Alliances between Business Partners
8.4.4 Teva Pharmaceutical Industries ltd
8.4.4.1 Business Description & Financial Analysis
8.4.4.2 SWOT Analysis
8.4.4.3 Products & Services Offered
8.4.4.4 Strategic Alliances between Business Partners
8.4.5 Natco Pharma Limited
8.4.5.1 Business Description & Financial Analysis
8.4.5.2 SWOT Analysis
8.4.5.3 Products & Services Offered
8.4.5.4 Strategic Alliances between Business Partners
8.4.6 Lupin
8.4.6.1 Business Description & Financial Analysis
8.4.6.2 SWOT Analysis
8.4.6.3 Products & Services Offered
8.4.6.4 Strategic Alliances between Business Partners
8.4.7 Sun Pharmaceutical Industries ltd
8.4.7.1 Business Description & Financial Analysis
8.4.7.2 SWOT Analysis
8.4.7.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.8 Merck & Co Inc
8.4.8.1 Business Description & Financial Analysis
8.4.8.2 SWOT Analysis
8.4.8.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.9 Eli Lilly and Company
8.4.9.1 Business Description & Financial Analysis
8.4.9.2 SWOT Analysis
8.4.9.3 Products & Services Offered
8.4.9.4 Strategic Alliances between Business Partners
8.4.10 Novartis AG
8.4.10.1 Business Description & Financial Analysis
8.4.10.2 SWOT Analysis
8.4.10.3 Products & Services Offered
8.4.10.4 Strategic Alliances between Business Partners
8.4.11 Other Companies
8.4.11.1 Business Description & Financial Analysis
8.4.11.2 SWOT Analysis
8.4.11.3 Products & Services Offered
8.4.11.4 Strategic Alliances between Business Partners
9 RESEARCH METHODOLOGY
9.1 Market Introduction
9.1.1 Market Definition
9.1.2 Market Scope & Segmentation
9.2 Information Procurement
9.2.1 Secondary Research
9.2.1.1 Purchased Databases
9.2.1.2 GMEs Internal Data Repository
9.2.1.3 Secondary Resources & Third Party Perspectives
9.2.1.4 Company Information Sources
9.2.2 Primary Research
9.2.2.1 Various Types of Respondents for Primary Interviews
9.2.2.2 Number of Interviews Conducted throughout the Research Process
9.2.2.3 Primary Stakeholders
9.2.2.4 Discussion Guide for Primary Participants
9.2.3 Expert Panels
9.2.3.1 Expert Panels Across 30+ Industry
9.2.4 Paid Local Experts
9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
9.3 Market Estimation
9.3.1 Top-Down Approach
9.3.1.1 Macro-Economic Indicators Considered
9.3.1.2 Micro-Economic Indicators Considered
9.3.2 Bottom Up Approach
9.3.2.1 Company Share Analysis Approach
9.3.2.2 Estimation of Potential Product Sales
9.4 Data Triangulation
9.4.1 Data Collection
9.4.2 Time Series, Cross Sectional & Panel Data Analysis
9.4.3 Cluster Analysis
9.5 Analysis and Output
9.5.1 Inhouse AI Based Real Time Analytics Tool
9.5.2 Output From Desk & Primary Research
9.6 Research Assumptions & Limitations
9.7.1 Research Assumptions
9.7.2 Research Limitations
LIST OF TABLES
1 Global Pharmacogenomics Market, By Application, 2020-2028 (USD Mllion)
2 Drug Discovery Market, By Region, 2020-2028 (USD Mllion)
3 Pain Management Market, By Region, 2020-2028 (USD Mllion)
4 Neurology Market, By Region, 2020-2028 (USD Mllion)
5 Oncology Market, By Region, 2020-2028 (USD Mllion)
6 Cardiovascular Diseases Market, By Region, 2020-2028 (USD Mllion)
7 Infectious Diseases Market, By Region, 2020-2028 (USD Mllion)
8 Psychiatry Market, By Region, 2020-2028 (USD Mllion)
9 Others Market, By Region, 2020-2028 (USD Mllion)
10 Global Pharmacogenomics Market, End User, 2020-2028 (USD Mllion)
11 Hospitals Market, By Region, 2020-2028 (USD Mllion)
12 Clinics Market, By Region, 2020-2028 (USD Mllion)
13 Research Institute Market, By Region, 2020-2028 (USD Mllion)
14 Medical, Academic Institute Market, By Region, 2020-2028 (USD Mllion)
15 Global Pharmacogenomics Market, By Technology, 2020-2028 (USD Mllion)
16 DNA Sequencing Market, By Region, 2020-2028 (USD Mllion)
17 Microarray Market, By Region, 2020-2028 (USD Mllion)
18 Polymerase Chain Reaction Market, By Region, 2020-2028 (USD Mllion)
19 Electrophoresis Market, By Region, 2020-2028 (USD Mllion)
20 Mass Spectrometry Market, By Region, 2020-2028 (USD Mllion)
21 Regional Analysis, 2020-2028 (USD Mllion)
22 North America Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
23 North America Pharmacogenomics Market, End User, 2020-2028 (USD Million)
24 North America Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
25 North America Pharmacogenomics Market, By Country, 2020-2028 (USD Million)
26 U.S Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
27 U.S Pharmacogenomics Market, End User, 2020-2028 (USD Million)
28 U.S Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
29 Canada Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
30 Canada Pharmacogenomics Market, End User, 2020-2028 (USD Million)
31 Canada Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
32 Mexico Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
33 Mexico Pharmacogenomics Market, End User, 2020-2028 (USD Million)
34 Mexico Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
35 Europe Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
36 Europe Pharmacogenomics Market, End User, 2020-2028 (USD Million)
37 Europe Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
38 Europe Pharmacogenomics Market, By country, 2020-2028 (USD Million)
39 Germany Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
40 Germany Pharmacogenomics Market, End User, 2020-2028 (USD Million)
41 Germany Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
42 U.K Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
43 U.K Pharmacogenomics Market, End User, 2020-2028 (USD Million)
44 U.K Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
45 France Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
46 France Pharmacogenomics Market, End User, 2020-2028 (USD Million)
47 France Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
48 Italy Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
49 Italy Pharmacogenomics Market, By End Use , 2020-2028 (USD Million)
50 Italy Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
51 Spain Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
52 Spain Pharmacogenomics Market, End User, 2020-2028 (USD Million)
53 Spain Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
54 Rest Of Europe Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
55 Rest Of Europe Pharmacogenomics Market, End User, 2020-2028 (USD Million)
56 Rest of Europe Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
57 Asia Pacific Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
58 Asia Pacific Pharmacogenomics Market, End User, 2020-2028 (USD Million)
59 Asia Pacific Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
60 Asia Pacific Pharmacogenomics Market, By Country, 2020-2028 (USD Million)
61 China Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
62 China Pharmacogenomics Market, End User, 2020-2028 (USD Million)
63 China Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
64 India Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
65 India Pharmacogenomics Market, End User, 2020-2028 (USD Million)
66 India Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
67 Japan Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
68 Japan Pharmacogenomics Market, End User, 2020-2028 (USD Million)
69 Japan Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
70 South Korea Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
71 South Korea Pharmacogenomics Market, End User, 2020-2028 (USD Million)
72 South Korea Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
73 Rest Of Asia Pacific Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
74 Rest Of Asia Pacific Pharmacogenomics Market, End User, 2020-2028 (USD Million)
75 Rest of Asia Pacific Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
76 Middle East and Africa Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
77 Middle East and Africa Pharmacogenomics Market, End User, 2020-2028 (USD Million)
78 Middle East and Africa Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
79 Middle East and Africa Pharmacogenomics Market, By Country, 2020-2028 (USD Million)
80 Saudi Arabia Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
81 Saudi Arabia Pharmacogenomics Market, End User, 2020-2028 (USD Million)
82 Saudi Arabia Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
83 UAE Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
84 UAE Pharmacogenomics Market, End User, 2020-2028 (USD Million)
85 UAE Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
86 Rest Of Middle East and Africa Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
87 Rest Of Middle East and Africa Pharmacogenomics Market, End User, 2020-2028 (USD Million)
88 Rest of Middle East and Africa Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
89 Central and South America Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
90 Central and South America Pharmacogenomics Market, End User, 2020-2028 (USD Million)
91 Central and South America Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
92 Central and South America Pharmacogenomics Market, By Country, 2020-2028 (USD Million)
93 Brazil Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
94 Brazil Pharmacogenomics Market, End User, 2020-2028 (USD Million)
95 Brazil Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
96 Rest Of Central and South America Pharmacogenomics Market, By Application, 2020-2028 (USD Million)
97 Rest Of Central and South America Pharmacogenomics Market, End User, 2020-2028 (USD Million)
98 Rest of Central and South America Pharmacogenomics Market, By Technology, 2020-2028 (USD Million)
99 Abbott: Products & Services Offering
100 Bayer AG: Products & Services Offering
101 AbbVie Inc: Products & Services Offering
102 Teva Pharmaceutical Industries ltd: Products & Services Offering
103 Natco Pharma Limited: Products & Services Offering
104 LUPIN: Products & Services Offering
105 Sun Pharmaceutical Industries ltd : Products & Services Offering
106 Merck & Co Inc: Products & Services Offering
107 Eli Lilly and Company, Inc: Products & Services Offering
108 Novartis AG: Products & Services Offering
109 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Pharmacogenomics Market Overview
2 Global Pharmacogenomics Market Value From 2020-2028 (USD Mllion)
3 Global Pharmacogenomics Market Share, By Application (2022)
4 Global Pharmacogenomics Market Share, End User (2022)
5 Global Pharmacogenomics Market Share, By Technology (2022)
6 Global Pharmacogenomics Market, By Region (Asia Pacific Market)
7 Technological Trends In Global Pharmacogenomics Market
8 Four Quadrant Competitor Positioning Matrix
9 Impact Of Macro & Micro Indicators On The Market
10 Impact Of Key Drivers On The Global Pharmacogenomics Market
11 Impact Of Challenges On The Global Pharmacogenomics Market
12 Porter’s Five Forces Analysis
13 Global Pharmacogenomics Market: By Application Scope Key Takeaways
14 Global Pharmacogenomics Market, By Application Segment: Revenue Growth Analysis
15 Drug Discovery Market, By Region, 2020-2028 (USD Mllion)
16 Pain Management Market, By Region, 2020-2028 (USD Mllion)
17 Neurology Market, By Region, 2020-2028 (USD Mllion)
18 Oncology Market, By Region, 2020-2028 (USD Mllion)
19 Cardiovascular Diseases Market, By Region, 2020-2028 (USD Mllion)
20 Infectious Diseases Market, By Region, 2020-2028 (USD Mllion)
21 Psychiatry Market, By Region, 2020-2028 (USD Mllion)
22 Others Market, By Region, 2020-2028 (USD Mllion)
23 Global Pharmacogenomics Market: End User Scope Key Takeaways
24 Global Pharmacogenomics Market, End User Segment: Revenue Growth Analysis
25 Hospitals Market, By Region, 2020-2028 (USD Mllion)
26 Clinics Market, By Region, 2020-2028 (USD Mllion)
27 Research Institute Market, By Region, 2020-2028 (USD Mllion)
28 Medical, Academic Institute Market, By Region, 2020-2028 (USD Mllion)
29 Global Pharmacogenomics Market: By Technology Scope Key Takeaways
30 Global Pharmacogenomics Market, By Technology Segment: Revenue Growth Analysis
31 DNA Sequencing Market, By Region, 2020-2028 (USD Mllion)
32 Microarray Market, By Region, 2020-2028 (USD Mllion)
33 Polymerase Chain Reaction Market, By Region, 2020-2028 (USD Mllion)
34 Electrophoresis Market, By Region, 2020-2028 (USD Mllion)
35 Mass Spectrometry Market, By Region, 2020-2028 (USD Mllion)
36 Regional Segment: Revenue Growth Analysis
37 Global Pharmacogenomics Market: Regional Analysis
38 North America Pharmacogenomics Market Overview
39 North America Pharmacogenomics Market, By Application
40 North America Pharmacogenomics Market, End User
41 North America Pharmacogenomics Market, By Technology
42 North America Pharmacogenomics Market, By Country
43 U.S. Pharmacogenomics Market, By Application
44 U.S. Pharmacogenomics Market, End User
45 U.S. Pharmacogenomics Market, By Technology
46 Canada Pharmacogenomics Market, By Application
47 Canada Pharmacogenomics Market, End User
48 Canada Pharmacogenomics Market, By Technology
49 Mexico Pharmacogenomics Market, By Application
50 Mexico Pharmacogenomics Market, End User
51 Mexico Pharmacogenomics Market, By Technology
52 Four Quadrant Positioning Matrix
53 Company Market Share Analysis
54 Abbott: Company Snapshot
55 Abbott: SWOT Analysis
56 Abbott: Geographic Presence
57 Bayer AG: Company Snapshot
58 Bayer AG: SWOT Analysis
59 Bayer AG: Geographic Presence
60 AbbVie Inc: Company Snapshot
61 AbbVie Inc: SWOT Analysis
62 AbbVie Inc: Geographic Presence
63 Teva Pharmaceutical Industries ltd: Company Snapshot
64 Teva Pharmaceutical Industries ltd: Swot Analysis
65 Teva Pharmaceutical Industries ltd: Geographic Presence
66 Natco Pharma Limited: Company Snapshot
67 Natco Pharma Limited: SWOT Analysis
68 Natco Pharma Limited: Geographic Presence
69 Lupin: Company Snapshot
70 Lupin: SWOT Analysis
71 Lupin: Geographic Presence
72 Sun Pharmaceutical Industries ltd : Company Snapshot
73 Sun Pharmaceutical Industries ltd : SWOT Analysis
74 Sun Pharmaceutical Industries ltd : Geographic Presence
75 Merck & Co Inc: Company Snapshot
76 Merck & Co Inc: SWOT Analysis
77 Merck & Co Inc: Geographic Presence
78 Eli Lilly and Company, Inc.: Company Snapshot
79 Eli Lilly and Company, Inc.: SWOT Analysis
80 Eli Lilly and Company, Inc.: Geographic Presence
81 Novartis AG: Company Snapshot
82 Novartis AG: SWOT Analysis
83 Novartis AG: Geographic Presence
84 Other Companies: Company Snapshot
85 Other Companies: SWOT Analysis
86 Other Companies: Geographic Presence
The Global Pharmacogenomics Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Pharmacogenomics Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
